LOW
58
-3
UNM
70
2
ALLE
41
-5
WDC
54
-3
ROK
40
-3
PHM
70
-4
AMG
52
-2
UPS
55
4
DO
83
2
IR
80
-5
ZION
55
-2
TXN
53
-2
ETN
80
-7
R
63
-5
RCL
66
4
FFIV
63
-3
MLM
67
-10
IP
65
3
IFF
56
-12
BLK
58
-3
LOW
58
-3
UNM
70
2
ALLE
41
-5
WDC
54
-3
ROK
40
-3
PHM
70
-4
AMG
52
-2
UPS
55
4
DO
83
2
IR
80
-5
ZION
55
-2
TXN
53
-2
ETN
80
-7
R
63
-5
RCL
66
4
FFIV
63
-3
MLM
67
-10
IP
65
3
IFF
56
-12
BLK
58
-3
Financhill
Back

Protalix BioTherapeutics Quote, Financials, Valuation and Earnings

Buy
60

PLX
Protalix BioTherapeutics

Last Price:
1.15
Seasonality Move:
0.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Protalix BioTherapeutics Price Quote

$1.15
+0.01 (+-1.71%)
(Updated: May 18, 2024 at 3:38 AM ET)

Protalix BioTherapeutics Key Stats

Buy
60
Protalix BioTherapeutics (PLX) is a Buy
Day range:
$1.13 - $1.16
52-week range:
$1.03 - $2.51
Dividend yield:
0%
P/E ratio:
13.00
P/S ratio:
1.60
P/B ratio:
2.88%
Volume:
189.2K
Avg. volume:
460.2K
1-year change:
-51.69%
Market cap:
$85.8M
Revenue:
$65.5M
EPS:
$0.01

How Much Does Protalix BioTherapeutics Make?

Is Protalix BioTherapeutics Growing As A Company?

Protalix BioTherapeutics Stock Price Performance

What Is Protalix BioTherapeutics 52-Week High & Low?

Protalix BioTherapeutics Price To Free Cash Flow

Is It Risky To Buy Protalix BioTherapeutics?

Is Protalix BioTherapeutics Cash Flow Positive?

  • What Is PLX Cash Flow From Operations?
    Cash flow from operations (TTM) is $5.9M
  • What Is Protalix BioTherapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $10.4M
  • What Is Protalix BioTherapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$22M

Protalix BioTherapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PLX return on invested capital is 13.65%
  • What Is Protalix BioTherapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 8.22%
  • What Is PLX Return On Equity?
    ROE is a measure of profitability and is 24.18%

Protalix BioTherapeutics Earnings Date & Stock Price

Protalix BioTherapeutics Competitors

Protalix BioTherapeutics Dividend Yield

Data Unavailable

Protalix BioTherapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: -60.91% -60.03%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 12.00
Upside from Last Price: 952.63%

Major Shareholders

  • How many PLX shares are owned by institutional investors?
    17.1M PLX shares are owned by institutional investors
  • How many PLX shares are owned by insiders?
    4.7M PLX shares are owned by insiders